Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2012) 29 P752

ICEECE2012 Poster Presentations Endocrine Disruptors (26 abstracts)

Treatment with resveratrol resulted in an inhibition of cell proliferation induced by 17 β-estradiol or various endocrine disrupting chemicals via down-regulating the cell cycle progression in BG-1 ovarian cancer cells

N. Kang , K. Hwang & K. Choi

Chungbuk National University, Cheongju, Republic of Korea.

Resveratrol (trans-3,4,5-trihydroxystilbene, RES), a phytoestrogen, exists in grape skin and red wine. Endocrine disrupting chemicals (EDCs) appear to promote the development and progression of the estrogen dependant cancers. In this study, we evaluated the inhibitory effect of RES on the cell growth and progression induced by various EDCs in BG-1 ovarian cancer cells expressing estrogen receptors (ERs). The various EDCs, i.e., bisphenol A (BPA), nonylphenol (NP), octylphenol (OP), methoxychlor (MXC), and hexabromocyclododecane (HBCD) were employed in this study. In the in vitro experiments, treatments of BG-1 cells with E2, BPA, NP, OP, MXC, or HBCD resulted in an increase of their growth. The treatment of BG-1 cells with ICI 182,780, a well known antagonist of ERs, reversed EDCs-induced cell growth in these cells, indicating that their growth-stimulatory effect is mediated through ERs. In addition, we evaluated the effect of RES in the presence of other EDCs by MTT assay. As a result, increased cell viability induced by these EDCs was reversed when co-cultured with RES. In addition, we further examined the regulation of cell cycle-dependent genes by RT-PCR. Concretely, the treatment with each EDC only decreased the gene expression of p21 and increased the expression of cell cycle-dependent kinase 2 (CDK2). However, co-treatment with RES and one of EDCs resulted in the increased gene expressions of p21 and the decreased expression of CDK2. Cyclin D1 was increased by down regulating p21 when only treated with each EDC in the absence of RES, while co-treatment with RES and each EDC decreased the gene expression of cyclin D1 by upregulating p21. Taken together, these results indicate that RES appears to be an inhibitor of Cyclin D1 and CDK2 and is responsible for the cell cycle arrest at G1 phase. In addition, when co-treated with each EDC, RES increased the expressions of p21 and resulted in the growth inhibition of BG-1 ovarian cancer cells. As a result, we confirmed the cell growth inhibitory effect of RES, a dietary phytoestrogen, on the estrogen-dependant ovarian cancer cells prompted by EDCs.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This work was supported, however funding details unavailable.

Volume 29

15th International & 14th European Congress of Endocrinology

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.